Non-invasive in vivo assessment of IDH1 mutational status in glioma
暂无分享,去创建一个
Daniel B Vigneron | Peder E Z Larson | Sarah J Nelson | P. Larson | S. Nelson | D. Vigneron | R. Pieper | J. Phillips | M. Chaumeil | S. Ronen | H. Yoshihara | Joanna J Phillips | Sabrina M Ronen | Myriam M Chaumeil | Hikari A I Yoshihara | Russell O Pieper | Olivia M Danforth | Olivia M. Danforth
[1] J. Berwick,et al. Kinetic modeling of hyperpolarized 13C pyruvate metabolism in tumors using a measured arterial input function , 2013, Magnetic resonance in medicine.
[2] Adam B Kerr,et al. Optimal variable flip angle schemes for dynamic acquisition of exchanging hyperpolarized substrates. , 2013, Journal of magnetic resonance.
[3] John Kurhanewicz,et al. Combined parallel and partial fourier MR reconstruction for accelerated 8‐channel hyperpolarized carbon‐13 in vivo magnetic resonance Spectroscopic imaging (MRSI) , 2013, Journal of magnetic resonance imaging : JMRI.
[4] P. Larson,et al. Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate , 2013, Science Translational Medicine.
[5] Fang Wang,et al. An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells , 2013, Science.
[6] W. Kaelin,et al. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. , 2013, Genes & development.
[7] T. Bathen,et al. 2-hydroxyglutarate as a magnetic resonance biomarker for glioma subtyping. , 2013, Translational oncology.
[8] O. Abdel-Wahab,et al. The Potential for Isocitrate Dehydrogenase Mutations to Produce 2-Hydroxyglutarate Depends on Allele Specificity and Subcellular Compartmentalization* , 2012, The Journal of Biological Chemistry.
[9] P. Kleihues,et al. The Definition of Primary and Secondary Glioblastoma , 2012, Clinical Cancer Research.
[10] T. Cloughesy,et al. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. , 2012, Neuro-oncology.
[11] Hui Yang,et al. IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives , 2012, Clinical Cancer Research.
[12] S. Gross,et al. Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo. , 2012, ACS medicinal chemistry letters.
[13] K. Smolková,et al. The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells , 2012, International journal of cell biology.
[14] Margarida Julià-Sapé,et al. Prospective diagnostic performance evaluation of single‐voxel 1H MRS for typing and grading of brain tumours , 2012, NMR in biomedicine.
[15] C. Rock,et al. Cancer-associated Isocitrate Dehydrogenase Mutations Inactivate NADPH-dependent Reductive Carboxylation* , 2012, The Journal of Biological Chemistry.
[16] A. Viale,et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012, Nature.
[17] Erwin G. Van Meir,et al. Detection of “oncometabolite” 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma , 2012, Journal of Molecular Medicine.
[18] S. Berger,et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.
[19] S. Weiss,et al. An in vivo patient-derived model of endogenous IDH1-mutant glioma. , 2012, Neuro-oncology.
[20] N. Alon,et al. Monoallelic expression determines oncogenic progression and outcome in benign and malignant brain tumors. , 2012, Cancer research.
[21] Mitchel S. Berger,et al. Magnetic Resonance of 2-Hydroxyglutarate in IDH1-Mutated Low-Grade Gliomas , 2012, Science Translational Medicine.
[22] Ovidiu C. Andronesi,et al. Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy , 2012, Science Translational Medicine.
[23] Kristen Scott,et al. Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma , 2012, NeuroImage.
[24] Dinesh Rakheja,et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated glioma patients , 2011, Nature Medicine.
[25] P. Boesiger,et al. A multi-sample 94 GHz dissolution dynamic-nuclear-polarization system. , 2012, Journal of magnetic resonance.
[26] Y. Xiong,et al. IDH 1 and IDH 2 Mutations in Tumorigenesis : Mechanistic Insights and Clinical Perspectives , 2012 .
[27] Hong Wu,et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy , 2012, Journal of Neuro-Oncology.
[28] Neil Clarke,et al. Dynamic nuclear polarization polarizer for sterile use intent , 2011, NMR in biomedicine.
[29] P. Larson,et al. In vivo measurement of normal rat intracellular pyruvate and lactate levels after injection of hyperpolarized [1-(13)C]alanine. , 2011, Magnetic resonance imaging.
[30] C. Brennan,et al. Molecular subclassification of diffuse gliomas: Seeing order in the chaos , 2011, Glia.
[31] R. Vijayaraghavan,et al. Toxicity of alpha-ketoglutarate following 14-days repeated oral administration in Wistar rats. , 2011, Cellular and molecular biology.
[32] Sarah J Nelson,et al. Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI , 2011, NMR in biomedicine.
[33] C. James,et al. Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging , 2011, Journal of magnetic resonance imaging : JMRI.
[34] John Kurhanewicz,et al. Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. , 2011, Neoplasia.
[35] James B. Mitchell,et al. Detecting response of rat C6 glioma tumors to radiotherapy using hyperpolarized [1‐13C]pyruvate and 13C magnetic resonance spectroscopic imaging , 2011, Magnetic resonance in medicine.
[36] Bin Wang,et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.
[37] Aaron E. Robinson,et al. In vivo comparison of total and hyperpolarized lactate levels assessed by localized 1 H MRS and hyperpolarized 13 C MRSI in glioblastoma models at 14 . 1 Tesla , 2011 .
[38] S. Ronen,et al. 17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2 , 2010, Breast Cancer Research.
[39] K. Uğurbil,et al. In vivo 13C spectroscopy in the rat brain using hyperpolarized [1-(13)C]pyruvate and [2-(13)C]pyruvate. , 2010, Journal of magnetic resonance.
[40] Adolf Pfefferbaum,et al. Metabolic imaging in the anesthetized rat brain using hyperpolarized [1‐13C] pyruvate and [1‐13C] ethyl pyruvate , 2010, Magnetic resonance in medicine.
[41] Omar Abdel-Wahab,et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.
[42] Adam B Kerr,et al. Investigation of tumor hyperpolarized [1‐13C]‐pyruvate dynamics using time‐resolved multiband RF excitation echo‐planar MRSI , 2010, Magnetic resonance in medicine.
[43] John Kurhanewicz,et al. Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. , 2010, Cancer research.
[44] Ilwoo Park,et al. Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors. , 2010, Neuro-oncology.
[45] R. McLendon,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[46] L. Liau,et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.
[47] Sarah E Bohndiek,et al. Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors , 2009, Proceedings of the National Academy of Sciences.
[48] Ken Chen,et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.
[49] Peder E. Z. Larson,et al. Multiband excitation pulses for hyperpolarized 13C dynamic chemical-shift imaging. , 2008, Journal of magnetic resonance.
[50] John Kurhanewicz,et al. Feasibility of using hyperpolarized [1-13C]lactate as a substrate for in vivo metabolic 13C MRSI studies. , 2008, Magnetic resonance imaging.
[51] John M Pauly,et al. Hyperpolarized C‐13 spectroscopic imaging of the TRAMP mouse at 3T—Initial experience , 2007, Magnetic resonance in medicine.
[52] Jan Wolber,et al. Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy , 2007, Nature Medicine.
[53] John M Pauly,et al. Double spin-echo sequence for rapid spectroscopic imaging of hyperpolarized 13C. , 2007, Journal of magnetic resonance.
[54] E. Gottlieb,et al. Cell-Permeating α-Ketoglutarate Derivatives Alleviate Pseudohypoxia in Succinate Dehydrogenase-Deficient Cells , 2007, Molecular and Cellular Biology.
[55] Jan Henrik Ardenkjaer-Larsen,et al. Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis. , 2006, Cancer research.
[56] J. Ardenkjær-Larsen,et al. Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[57] K. Lamborn,et al. Growth of human glioblastomas as xenografts in the brains of athymic rats. , 2002, In Vivo.
[58] H. Fatania,et al. Chemical modification of rat liver cytosolic NADP+‐linked isocitrate dehydrogenase by N‐ethylmaleimide Evidence for essential sulphydryl groups , 1993, FEBS letters.
[59] R. Shank,et al. 2-Oxoglutarate Transport: Regulating Glutamate and Intermediates in Neurons* A Potential Mechanism for Tricarboxylic Acid Cycle , 1993 .